Man at a kitchen counter with loose capsules and an amber glass, illustrating NMN and NAD+ supplements
Supplements··9 min briefing

NMN and David Sinclair: Does the Anti-Aging Supplement Actually Work?

NMN raises NAD+, and that part is settled. What it has not done yet is change anything you would notice. Here is how to pick a bottle that actually contains what the label says, how to take it, and what the 2026 research changed.

Updated August 2026 · Reviewed by Roy Sañudo S.

NMN and David Sinclair: Does the Anti-Aging Supplement Actually Work?

0:00 / 9 min briefing

Speed:
Read transcript

Key Takeaways

  • NMN reliably raises NAD+ in your blood, and at the doses tested it appears safe and well tolerated
  • Choosing the bottle matters more than choosing the brand: in one lab test, 3 of 15 NMN products contained no detectable NMN
  • Start at 300 mg, take it at whatever hour you will remember, and do not pay extra for sublingual
  • Pooled results from every published trial show no clear effect yet on blood sugar, cholesterol, or muscle strength
  • The famous trial that held a biological age score steady was funded by the two companies that make the NMN it tested

You are probably here because a Harvard professor takes this every morning, and you want to know whether you should too.

Short answer: NMN does one thing reliably, which is raise NAD+ in your blood. That part is settled. What it has not yet done is produce a change you would notice. And if you decide to try it anyway, the biggest risk is not the molecule. It is the bottle: in one lab test, three of fifteen NMN products contained no detectable NMN at all.

So this page is a practical guide. What NMN is, how to choose a bottle that is real, how to take it, what the science does and does not support, and what is coming next.

What NMN is, and what it does

NMN is a building block your body turns into NAD+.

Think of each cell as a small kitchen. It has to cook, turning food into energy, and clean up after itself, repairing the damage of being alive. NAD+ is the multitool the staff need for both jobs. You cannot swallow the multitool, because your gut takes it apart on the way, so you swallow flat-pack parts and let your body assemble them inside. Those parts are called precursors, and the two main ones are NMN and NR.

Here is the part that is genuinely well established: take NMN and your blood NAD+ goes up. It is replicated across human trials, and even NMN's critics accept it. At the doses tested, over a few months, it also appears safe and well tolerated. Supporters and critics do not argue about this part.

How to choose a bottle

This is where your money is actually at risk, so it comes before everything else.

Researchers at the National University of Singapore and Vrije Universiteit Amsterdam bought 15 NMN products off the shelf and measured what was inside. Content ranged from 0% to 104.5% of the label. Only 7 of the 15 came within 10% of their claim. Three contained no detectable NMN at all. (GeroScience, 2024, PMID 38935229.)

One in five bottles was, chemically speaking, a jar of nothing.

So independent testing is the whole game. Look for verification by an outside lab such as NSF or USP, on the batch you are buying. It is rare for NMN, but it exists. If a company will not show you that test, you have your answer, and that single check is worth more than any comparison of brands.

How to take it

Start at 300 mg. Human trials used 300 to 900 mg a day, and the manufacturers' own trial pointed at 600 mg as its best dose. Sinclair takes 1 gram. More has never been shown to be better, so the low end is the sensible place to begin.

The hour does not matter, so take it when you will remember. You will read everywhere that NMN must be taken in the morning because NAD+ peaks with daylight. That advice comes from mouse studies. The one human study that tracked NAD+ in the brain across the day found no meaningful morning-to-afternoon difference, and no trial has ever compared morning against evening dosing on any outcome. Consistency is the part that matters.

Do not pay extra for sublingual. Tablets that dissolve under your tongue are sold on a promise of better absorption. In 2026 researchers finally tested it, giving 14 men NMN both ways. Blood NMN and NAD+ came out the same, and the sublingual route only produced breakdown products faster (*Scientific Reports*, 2026).

Cost it honestly. At 600 mg a day, a year runs from a few hundred to over a thousand dollars, depending on the brand.

Give it 60 days, then judge. Note how you feel at the start and at the end, and trust your own experience over the marketing.

Where you can legally buy it

United States: yes, since December 2025. The FDA ruled in late 2022 that NMN could not be sold as a supplement, Amazon delisted it in March 2023, then a trade group petitioned and sued and the agency reversed itself in letters dated 29 September 2025, confirmed that December.

European Union: not on a shop shelf. NMN has never been authorised as a "novel food". In May 2026 the European Food Safety Authority issued a first positive safety opinion on one form at 300 mg a day, but European Commission authorisation had not followed as of July 2026. A shop in France or Spain cannot lawfully sell it to you. That is a rule about selling, not about you, so if a website is happily shipping it into Europe, now you know.

What the science has not shown yet

This is the honest part, and it is short.

Independent teams have pooled every published human trial. Blood sugar and cholesterol: eight trials, 342 people, no clear effect (Current Diabetes Reports, 2024, PMID 39531138). Muscle: ten trials of NMN and NR, no clear effect on muscle mass, grip strength, walking speed, or the time it takes to stand up from a chair (Journal of Cachexia, Sarcopenia and Muscle, 2025, PMID 40275690). Blood pressure: ten trials, 349 people, and one modest finding, with the lower number falling by about 2 mmHg (*Nutrients*, 2026).

The trial that made NMN famous is the one you have heard of. Eighty middle-aged adults, 60 days, and a "biological age" score that climbed in the placebo group while holding steady in all three NMN groups (GeroScience, 2023, PMID 36482258). Two details change how you read it. That score came from a calculator called Aging.Ai 3.0, which estimates your age from 19 routine blood-test values, so it is blood chemistry rather than a reading of your cells, and a different instrument from the epigenetic clocks that measure marks on your DNA. And the trial was fully funded by Aba Chemicals and Abinopharm, the companies that make the NMN it tested, with three of its ten authors working for them.

None of that makes it worthless. It means the strongest result we have comes from an interested party, and it is a starting point rather than a verdict.

Should it convince you that David Sinclair takes it?

He takes 1 gram of NMN and 1 gram of resveratrol each morning, stirred into yogurt. Dr. David Sinclair is a professor of genetics at Harvard Medical School, he has studied this molecule for years, and he lists his commercial ties openly on his lab's website. That list is long, and it spans companies built on the molecule he recommends.

His reasoning is clean: NMN is the fuel, resveratrol is the accelerator. Two parts of it have worn badly. The accelerator claim rests on a lab experiment from 2003 in which researchers glued a small glowing marker onto the molecule sirtuins were meant to act on, and teams at Amgen and Pfizer later showed the effect largely depended on that marker being there. And in 2024 he described a dog supplement from a company he co-founded as "proven to reverse aging", with no published research behind the claim, and resigned as president of the Academy for Health and Lifespan Research after the backlash.

Here is the part worth sitting with. The typical NMN article gives you two proofs: a landmark trial, and "even the Harvard professor takes it." They look like two independent signals pointing the same way. They are closer to one. The trial was funded by NMN manufacturers, and the professor's companies are built on the same molecule. That is not a conspiracy. It is the same incentive, counted twice.

The other side of the argument has the same problem, and to their credit both men say so out loud. Dr. Charles Brenner identified NR as an NAD+ building block at Dartmouth in 2004, and his team ran the first human study showing an NR pill raises NAD+ (2016, PMID 27721479), which gave one dose to 12 people and measured blood levels only. A later six-week trial at the University of Colorado Boulder found NR safe and NAD+ raised, with a small blood-pressure drop mostly among people who started high, and its authors called that a reason to run a bigger trial, not a result (2018, PMID 29599478). Brenner is also chief scientific advisor at the company that sells NR, and his group published the rebuttal to the 2019 paper claiming NMN has its own doorway into your cells (PMID 31131364). If your body breaks NMN down into NR first and rebuilds it inside, the whole rivalry may be smaller than it looks.

What is new, and what to watch

The 2026 result that complicates the story. Two independent studies from Amsterdam UMC, published in *Nature Metabolism*, measured NAD+ in the whole blood of several groups of people. It did not track age. It did not move with lifestyle either.

Blood is not the same as tissue. Almost everything a supplement company can show you comes from blood, because blood is what you can draw out of an arm. Almost everything that matters about aging happens inside muscle, brain, liver and skin. So we can reliably raise a number, in the one compartment where that number does not appear to track aging. That is not proof NMN does nothing, because NAD+ may genuinely fall in tissues that blood does not represent, and that is exactly where any real benefit would have to happen.

What would settle it: a large, long, independently funded trial measuring real health outcomes rather than blood chemistry. Those trials are running, and the answer may improve.

Meanwhile, the free levers already clear the bar. Held to the same standard we just held NMN to: when you eat, where people with metabolic syndrome eating inside a 10-hour window lost weight and lowered their blood pressure, in a small study with no comparison group whose own food logs show they also ate about 200 calories a day less (Cell Metabolism, 2020, PMID 31813824, n=19); exercise, where older adults who walked regularly grew the front of the hippocampus by about 2% over a year while a stretching group's shrank, although the walkers did not beat the stretchers on the memory test and pooling eight later trials in 554 people found no clear volume effect (PNAS, 2011, PMID 21282661); and cold exposure, where experienced winter swimmers generated more heat in response to cold, though their brown fat was no more active than anyone else's and they paired the cold with hot sauna (Cell Reports Medicine, 2021, PMID 34755128). Independent teams, different countries, funded by nobody selling the thing. If you want to see them stacked into one ordinary week, here is how Roy lives.

What to do tomorrow

Nothing that costs money.

Open the website of the NMN brand you were considering, and look for one thing: a test of the batch you would actually receive, done by an outside lab, with a date on it. Not a certificate from the manufacturer. Not a badge on the packaging. A test, of that batch, by someone else.

Give it two minutes. If you cannot find it, you have your answer, and you have just saved yourself a year's money.

If you can find it, you are in the small group of buyers who checked. Then go in with clear eyes: start at 300 mg, take it consistently, give it 60 days, and be honest with yourself about what changed.

We would rather tell you that than sell you a clock that stopped.

Where the science stands

Our read after cross-checking every study and expert view.

Key findings

  • Strong evidenceNMN raises NAD+ in your blood. This is replicated across human trials and even NMN's critics accept it.
  • Strong evidencePooled analyses of all published trials find no clear effect on blood sugar, cholesterol, or muscle strength. One found a small drop in diastolic blood pressure.
  • Strong evidenceThe trial that made NMN famous was fully funded by the two companies that make it, and its 'biological age' came from a blood-chemistry calculator, not a DNA clock.
  • Moderate evidenceTwo independent 2026 studies found that NAD+ in whole blood does not track age or lifestyle, which weakens the link between raising it and aging more slowly.

Where the research agrees

Every expert view we checked agrees on two things: NMN raises NAD+ in the blood, and at the doses tested for a few months it appears safe and well tolerated. Supporters and critics do not argue about this part.

Where it's still debated

Whether raising NAD+ does anything you would actually feel. Supporters point to one manufacturer-funded trial; independent pooled analyses find almost nothing. The test that would settle it: a large, long, independently funded trial measuring real health outcomes rather than blood chemistry.

Scientific References

This article synthesizes research from the following institutions and studies. All content is derived from peer-reviewed scientific literature and leading research centers.

Harvard Medical School, Department of Genetics (Dr. David Sinclair)

Yi et al., GeroScience: "The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, double-blind, placebo-controlled, dose-dependent clinical trial" (2023). PMID 36482258. Note: the paper states it was fully funded by Aba Chemicals and Abinopharm, the manufacturers of the NMN tested; 3 of 10 authors are their employees. "Biological age" was estimated with the Aging.Ai 3.0 blood-biomarker calculator, not an epigenetic clock.

Chen et al., Current Diabetes Reports: "Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials" (2024; 8 RCTs, n=342; no significant effect). PMID 39531138

Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle: "The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis" (2025; 10 trials; no significant pooled effect). PMID 40275690. DOI 10.1002/jcsm.13799

Zhang et al., Nutrients: "Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" (2026; 10 RCTs, n=349; diastolic BP -2.15 mmHg). DOI 10.3390/nu18060890

Trętowicz et al., Nature Metabolism: "Human whole-blood NAD+ levels do not vary with age or lifestyle interventions" (Amsterdam UMC, 2026). DOI 10.1038/s42255-026-01537-5

Nature Metabolism: "Whole-blood NAD+ levels do not reflect healthy ageing" (2026). DOI 10.1038/s42255-026-01540-w

Sandalova, Lim et al., GeroScience: "Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim" (National University of Singapore and Vrije Universiteit Amsterdam, 2024; 15 products, 0-104.5% of label, 3 with no detectable NMN). PMID 38935229. DOI 10.1007/s11357-024-01257-2

Wakabayashi et al., Scientific Reports: "Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men" (2026; n=14 crossover; no difference in blood NMN or NAD+ between routes). DOI 10.1038/s41598-026-57552-9

Bieganowski & Brenner, Cell: "Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans" (Dartmouth Medical School, 2004). PMID 15137942

Trammell et al., Nature Communications: "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans" (University of Iowa, 2016; n=12 single-dose pharmacokinetic study). PMID 27721479. DOI 10.1038/ncomms12948

Martens et al., Nature Communications: "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults" (University of Colorado Boulder, 2018; n=24 crossover). PMID 29599478. DOI 10.1038/s41467-018-03421-7

Grozio et al., Nature Metabolism: "Slc12a8 is a nicotinamide mononucleotide transporter" (2019; rebutted by Schmidt & Brenner, "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter", Nature Metabolism 2019, DOI 10.1038/s42255-019-0085-0). PMID 31131364. DOI 10.1038/s42255-018-0009-4

Massudi et al., PLOS ONE: "Age-associated changes in oxidative stress and NAD+ metabolism in human tissue" (2012; n=49 skin samples; the origin of the widely repeated "NAD+ halves by 60" claim, which the study did not measure). DOI 10.1371/journal.pone.0042357

US FDA: NMN dietary-supplement exclusion (2022), reversed by agency letters dated 29 September 2025 and confirmed December 2025

Singh P., Gollapalli K., ... Yadav V.K., Science: "Taurine deficiency as a driver of aging" (2023). PMID 37289866. DOI 10.1126/science.abn9257. Lifespan extension in mice and worms, health-span improvement in monkeys; the HUMAN data is cross-sectional correlation only. The authors conclude clinical trials "seem warranted." Columbia University filed provisional patent applications naming the senior author as an inventor, disclosed in the paper.

Fernandez M.E. et al., Science: "Is taurine an aging biomarker?" (2025). PMID 40472098. DOI 10.1126/science.adl2116. Three human cohorts measured LONGITUDINALLY — the NIA Baltimore Longitudinal Study of Aging, a Balearic Islands cohort (IdISBa, Mallorca) and the Atlanta PREMED cohort (Emory) — plus monkeys and mice. Circulating taurine increased or stayed unchanged with age, with high within- and between-person variability.

Marcangeli V. et al., Aging Cell: "Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans" (2025). PMID 41061678. n=137 men aged 20-93, Université du Québec à Montréal. No association between circulating taurine and age, muscle mass, strength, physical performance or mitochondrial function. Male-only sample.

van Stijn M.F. et al., Int J Mol Sci: "Effect of oral taurine on morbidity and mortality in elderly hip fracture patients: a randomized trial" (2015). PMID 26035756. n=236, aged 75+, 6 g/day. PRIMARY endpoint (in-hospital morbidity, 1-year morbidity/mortality) NOT met; a secondary oxidative-stress marker improved.

Abud G.F. et al., Nutrition: "Taurine as a possible antiaging therapy: A controlled clinical trial on taurine antioxidant activity in women ages 55 to 70" (2022). PMID 35700594. n=24, 1.5 g/day, 16 weeks. What rose was superoxide dismutase, an antioxidant enzyme — not an aging endpoint. Underpowered.

Chupel M.U. et al., Appl Physiol Nutr Metab: "Exercise and taurine in inflammation, cognition, and peripheral markers of blood-brain barrier integrity in older women" (2018). PMID 29474803. n=48. Cognition (MMSE) improved only in the exercise-plus-taurine arm; taurine alone moved two inflammation markers and not cognition.

Technical University of Munich, ClinicalTrials.gov NCT06613542: 90 adults aged 55-75, 4 g/day taurine vs placebo, 6 months, with BIOLOGICAL AGE as the primary outcome measured by DNA methylation and by proteomic analysis. Status COMPLETED 13 November 2025; results not published as of August 2026.

Rana S.K. & Sanders T.A., Br J Nutr: "Taurine concentrations in the diet, plasma, urine and breast milk of vegans compared with omnivores" (1986). PMID 3676193. Taurine was ABSENT from the vegan diet and urinary taurine was under half that of omnivores, yet plasma levels were only slightly lower — endogenous synthesis holds the circulating level up.

European Food Safety Authority: first positive safety opinion on beta-NMN at 300 mg/day (May 2026). NMN remains unauthorized as an EU novel food pending European Commission authorization.

Curated by Roy Sañudo S.

Research Curator, Anima Cosmi

Anima Cosmi translates peer-reviewed research from Harvard, Oxford, Stanford, the Salk Institute, and other leading labs into plain language. Every article names its researchers, institutions, and publication years, so you can check the sources yourself.

Not medical advice. Anima Cosmi is a research curator, not a medical practice: this is education, not a prescription. Talk to a qualified healthcare provider before starting any new supplement, diet, or routine, especially if you take medication or have a health condition.


Continue Reading